Skip to content

Jodi L Smith

4 papers in the library · 138 citations · publishing 2019-2024

Papers

Sort Most recent Most cited

(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders.

International Journal of Molecular Sciences June 20, 2024 Hana Shafique, Julie C Demers, Julia Biesiada et al. 29 citations

NMDA receptor antagonists have potential for therapeutics in neurological and psychiatric diseases, including neurodegenerative diseases, epilepsy, traumatic brain injury, substance abuse disorder (SUD), and major depressive disorder (MDD). (S)-ketamine was the first of a novel class of antidepressants, rapid-acting antidepressants, to be approved for medical use. The stereoisomer, (R)-ketamine...

DOI: 10.3390/ijms25126804 (opens in new tab) Full text (opens in new tab) R-ketamine Major depressive disorder Substance use disorder Inflammation +5

Clinical pharmacological innovation in the treatment of depression.

Expert Review of Clinical Pharmacology April 1, 2023 Jeffrey M. Witkin, Lalit K Golani, Jodi L Smith 18 citations

Deficiencies in standard of care antidepressants are driving novel drug discovery. A new age of antidepressant medications has emerged with the introduction of rapid-acting antidepressants with efficacy in treatment-resistant patients. The newly approved medicines and those in clinical development for major depressive disorder (MDD) are documented in this scoping review of newly approved and...

DOI: 10.1080/17512433.2023.2198703 (opens in new tab) Full text (opens in new tab) Ketamine Major depressive disorder Treatment-resistant depression Antidepressant +2

Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism

Expert Opinion on Drug Discovery August 8, 2022 Andrzej Pilc, Agata Machaczka, Paweł Kawalec et al. 20 citations

INTRODUCTION: Major depressive disorder remains a prevalent world-wide health problem. Currently available antidepressant medications take weeks of dosing, do not produce antidepressant response in all patients, and have undesirable ancillary effects. AREAS COVERED: The present opinion piece focuses on the major inroads to the creation of new antidepressants. These include N-methyl-D-aspartate...

DOI: 10.1080/17460441.2022.2111415 (opens in new tab) Major depressive disorder Antidepressant Pharmacology Ampa receptor +5

Rapid-acting antidepressants.

Advances in pharmacology (San Diego, Calif.) 2019 Jeffrey M. Witkin, Anna E Martin, Lalit K Golani et al. 71 citations

Conventional antidepressants (biogenic amine mechanisms) are not fully efficacious (e.g., symptoms remain after treatment, not all patients respond), produce effects only after weeks of daily dosing, and do not impact all disease symptoms. In contrast, a new class of antidepressants has been emerging since 2006 that has demonstrated rapid onset, large effect size, activity after only a single...

DOI: 10.1016/bs.apha.2019.03.002 (opens in new tab) Full text (opens in new tab) Ketamine Gabaa α5 Psychedelic drugs Rapid-acting antidepressants +2